ArticleOncogenesis2026
Cyclin E modulates vulnerability to CDC7 kinase inhibition.
Article in Oncogenesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
CCNE1 (cyclin E) is frequently amplified or overexpressed in triple-negative breast cancer (TNBC) as compared with luminal subtypes. Cyclin E is associated with chromosomal instability and poor outcome, and overexpression promotes replication stress (fork stalling) in S-phase through impaired MCM chromatin loading and deregulated replication origin firing. Thus, approaches leveraging cyclin E-induced replication stress could lead to the development of promising therapeutic strategies. Here, we studied the effects of cell division cycle 7 (CDC7) kinase inhibition in TNBC cells overexpressing cyclin E. Cyclin E overexpression enhanced sensitivity to CDC7 inhibition, reducing proliferation and colony-forming capacity. This was accompanied by delays in replication timing and cell accumulation with ≥4 N DNA content. Conversely, CCNE1 knockdown rescued proliferation and colony outgrowth in the presence of CDC7 inhibition and reversed accumulation with ≥ 4N DNA content. CRISPR screening revealed cyclin-dependent kinase 8 (CDK8) as conferring resistance to CDC7 inhibition in a CCNE1-amplified cell line. Combined CDC7 and CDK8 inhibition significantly reduced proliferation and colony-forming ability, led to ≥4 N DNA content, and reduced tumor volume and mass in vivo. Together, this work identifies the enhanced vulnerability of cyclin E-overexpressing TNBC cells to CDC7 kinase inhibition and substantial synergy when combined with CDK8 inhibition.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.